University of Hull logo

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status

Hodgkinson, Victoria C.; Eagle, Gina L.; Drew, Philip J.; Lind, Michael J.; Cawkwell, Lynn

Authors

Victoria C. Hodgkinson

Gina L. Eagle

Philip J. Drew

Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies

Abstract

This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (shotgun and quantitative) mass spectrometry approaches are discussed. Non-mass spectrometry approaches including antibody microarray platforms are described as complementary proteomic strategies. Methods for technical confirmation and clinical validation of putative biomarkers are presented. Use of this proteomic toolbox in the quest for biomarkers of chemotherapy resistance in breast cancer is reviewed. Technical aspects of sample selection, acquisition, storage and analysis are discussed and putative biomarkers identified through proteomic approaches are presented. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Journal Article Type Review
Publication Date Aug 1, 2010
Journal CANCER LETTERS
Print ISSN 0304-3835
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 294
Issue 1
Pages 13-24
Institution Citation Hodgkinson, V. C., Eagle, G. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2010). Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Letters, 294(1), (13-24). doi:10.1016/j.canlet.2010.01.036. ISSN 0304-3835
DOI https://doi.org/10.1016/j.canlet.2010.01.036
Keywords 2D gels; Breast cancer; Chemotherapy resistance; Mass spectrometry; Microarrays; Proteomics